Zurcher Kantonalbank (Zurich Cantonalbank) Summit Therapeutics Inc. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$39 Billion
Q2 2025

A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 628 shares of SMMT stock, worth $17,998. This represents 0.0% of its overall portfolio holdings.

Number of Shares

628

Previous 736 14.67%

Holding current value

$17,998

Previous $14,000 7.14%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 07, 2025	SELL	$16.64 - $36.7 $1,797 - $3,963	-108 Reduced 14.67%	628 $13,000
Q1 2025 May 07, 2025	SELL	$16.65 - $23.76 $79,087 - $112,860	-4,750 Reduced 86.58%	736 $14,000
Q4 2024 Feb 07, 2025	SELL	$17.52 - $23.46 $19,727 - $26,415	-1,126 Reduced 17.03%	5,486 $97,000
Q3 2024 Nov 07, 2024	SELL	$6.89 - $31.93 $1,019 - $4,725	-148 Reduced 2.19%	6,612 $144,000
Q2 2024 Jul 29, 2024	SELL	$2.39 - $10.92 $77,036 - $351,984	-32,233 Reduced 82.66%	6,760 $52,000
Q1 2024 Apr 25, 2024	SELL	$2.55 - $5.07 $1,871 - $3,721	-734 Reduced 1.85%	38,993 $161,000
Q4 2023 Jan 30, 2024	BUY	$1.67 - $2.83 $23,543 - $39,897	14,098 Added 55.01%	39,727 $103,000
Q3 2023 Oct 25, 2023	SELL	$1.54 - $2.42 $1,005 - $1,580	-653 Reduced 2.48%	25,629 $47,000
Q2 2023 Aug 07, 2023	BUY	$1.32 - $2.81 $27,149 - $57,796	20,568 Added 359.96%	26,282 $65,000
Q1 2023 May 08, 2023	BUY	$1.38 - $5.41 $7,885 - $30,912	5,714 New	5,714 $9,000

Others Institutions Holding SMMT

# of Institutions

246

Shares Held

87.3M

Call Options Held

1.77M

Put Options Held

2.49M

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $5.77B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account

Zurcher Kantonalbank (Zurich Cantonalbank) Summit Therapeutics Inc. Transaction History